NASDAQ · SYRE
Spyre Therapeutics, Inc.
$96.07-$2.89 (-2.92%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
Loading market information…
NASDAQ · ERYP · USD
Stock price, earnings
Quote as of Jun 28, 2023, 07:48 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ERYTECH Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ERYTECH Pharma S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$96.07-$2.89 (-2.92%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
$0.68-$0.04 (-5.84%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.61% below the high.
$0.88+$0.01 (+1.49%)
Kronos Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
$9.81+$0.39 (+4.14%)
AlloVir, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.38% below the high.
$4.97$0.00 (0.0%)
bluebird bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.62% below the high.
$0.30-$0.00 (-0.03%)
GreenLight Biosciences Holdings’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
$0.70-$0.06 (-7.74%)
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
$1.00-$0.03 (-2.91%)
Pluristem Therapeutics Inc.: Healthcare · Biotechnology.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
